These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38843843)

  • 21. Effect of immune-modulating metronomic capecitabine as an adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma.
    He Q; Luo X; Liu L; Zhao C; Li Z; Jin F
    BMC Immunol; 2024 May; 25(1):28. PubMed ID: 38710996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area.
    Fangzheng W; Chuner J; Haiyan Q; Quanquan S; Zhimin Y; Tongxin L; Jiping L; Peng W; Kaiyuan S; Zhenfu F; Yangming J
    Medicine (Baltimore); 2019 Dec; 98(51):e18484. PubMed ID: 31861031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
    Tang LL; Guo R; Zhang N; Deng B; Chen L; Cheng ZB; Huang J; Hu WH; Huang SH; Luo WJ; Liang JH; Zheng YM; Zhang F; Mao YP; Li WF; Zhou GQ; Liu X; Chen YP; Xu C; Lin L; Liu Q; Du XJ; Zhang Y; Sun Y; Ma J
    JAMA; 2022 Aug; 328(8):728-736. PubMed ID: 35997729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative study of locoregionally advanced nasopharyngeal carcinoma treated with intensity modulated irradiation and platinum-based chemotherapy.
    Xu JH; Guo WJ; Bian XH; Wu JF; Jiang XS; Guo YS; He X
    Cancer Radiother; 2013; 17(4):297-303. PubMed ID: 23849438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incorporation of PD-1 blockade into induction chemotherapy improved tumor response in patients with locoregionally advanced nasopharyngeal carcinoma in a retrospective patient cohort.
    Yao Y; Ouyang Q; Wang S; Li K; Luo Q; Qiu L; Liu F; Tan L; Li Q; Ren B; Long P; Ye J; Zhong X
    Oral Oncol; 2024 Jul; 154():106867. PubMed ID: 38797001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reducing Target Volumes of Intensity Modulated Radiation Therapy After Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Long-Term Results of a Prospective, Multicenter, Randomized Trial.
    Xiang L; Rong JF; Xin-Chen ; Li XY; Zheng Y; Ren PR; Lin S; Wen QL; He LJ; Zhang JW; Shang CL; Yang HR; Fan J; Pang HW; Zhang J; Tan BX; Zhang L; Du XB; Wen SM; Jiang L; Qin G; Wu JB
    Int J Radiat Oncol Biol Phys; 2023 Nov; 117(4):914-924. PubMed ID: 37356553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Current management and perspectives for locally advanced nasopharyngeal carcinoma].
    Mnejja W; Nouri O; Fourati N; Dhouib F; Siala W; Charfeddine I; Khanfir A; Farhat L; Daoud J
    Cancer Radiother; 2022 Sep; 26(5):730-735. PubMed ID: 35249815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes of carbon-ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma.
    Hu J; Huang Q; Gao J; Guan X; Hu W; Yang J; Qiu X; Chen M; Kong L; Lu JJ
    Cancer; 2020 Dec; 126(23):5173-5183. PubMed ID: 32931035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases.
    Lin S; Lu JJ; Han L; Chen Q; Pan J
    BMC Cancer; 2010 Feb; 10():39. PubMed ID: 20146823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment outcomes for different subgroups of nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy.
    Su SF; Han F; Zhao C; Huang Y; Chen CY; Xiao WW; Li JX; Lu TX
    Chin J Cancer; 2011 Aug; 30(8):565-73. PubMed ID: 21801605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of intensity-modulated radiation therapy alone vs. intensity-modulated radiation therapy combined with chemotherapy in elderly nasopharyngeal carcinoma patients (aged >65 years).
    Mi JL; Meng YL; Wu HL; Cao YL; Zhang B; Pan YF; Zhou YY; Fan JF; Liao SF; Qin XL; Yao DC; Jiang W
    Strahlenther Onkol; 2020 Mar; 196(3):270-279. PubMed ID: 31748837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review).
    Huang H; Yao Y; Deng X; Huang Z; Chen Y; Wang Z; Hong H; Huang H; Lin T
    Int J Oncol; 2023 Aug; 63(2):. PubMed ID: 37417358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor Regression and Patterns of Distant Metastasis of T1-T2 Nasopharyngeal Carcinoma with Intensity-Modulated Radiotherapy.
    Wu MY; He XY; Hu CS
    PLoS One; 2016; 11(4):e0154501. PubMed ID: 27119991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experience with combination of cisplatin plus gemcitabine chemotherapy and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
    He X; Ou D; Ying H; Zhu G; Hu C; Liu T
    Eur Arch Otorhinolaryngol; 2012 Mar; 269(3):1027-33. PubMed ID: 21706324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Impact of changing gross tumor volume delineation of intensity-modulated radiotherapy on the dose distribution and clinical treatment outcome after induction chemotherapy for the primary locoregionally advanced nasopharyngeal carcinoma].
    Yu Z; Luo W; Zhou QC; Zhang QH; Kang DH; Liu MZ
    Ai Zheng; 2009 Nov; 28(11):1132-7. PubMed ID: 19895731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution.
    Fangzheng W; Chuner J; Zhiming Y; Tongxin L; Fengqin Y; Lei W; Bin L; Fujun H; Ming C; Weifeng Q; Zhenfu F
    Oncol Res; 2018 Mar; 26(2):277-287. PubMed ID: 29046165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma.
    Aftab O; Liao S; Zhang R; Tang N; Luo M; Zhang B; Shahi S; Rai R; Ali J; Jiang W
    Radiat Oncol; 2020 Mar; 15(1):66. PubMed ID: 32178698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term results of the phase II dose and volume de-escalation trial for locoregionally advanced nasopharyngeal carcinoma.
    Xue F; Ou D; Ou X; Zhou X; Hu C; He X
    Oral Oncol; 2022 Nov; 134():106139. PubMed ID: 36179488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensity-modulated radiotherapy combined with endostar has similar efficacy but weaker acute adverse reactions than IMRT combined with chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma.
    Kang M; Wang F; Liao X; Zhou P; Wang R
    Medicine (Baltimore); 2018 Jun; 97(25):e11118. PubMed ID: 29924009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term survival and late complications of intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma.
    Kong F; Zhou J; Du C; He X; Kong L; Hu C; Ying H
    BMC Cancer; 2018 Nov; 18(1):1139. PubMed ID: 30453915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.